Cramer's lightning round: Onto Innovation is 'going to go lower'
A recap of Jim Cramer’s Mad Money lightning-round-style discussion features varied stock takes from a panel. Onto Innovation is forecast to decline, framed as overpriced in a Fed-tightened environment, while other names receive mixed-to-optimistic or cautious theses, such as UiPath being inexpensive but lacking catalysts and Affirm advocating a staged entry. The conversations reflect a risk-tolerant stance toward some names and a bearish tilt on others, with room for tactical buys and patience depending on price levels and macro signals. The segment underscores prevailing market tension between inflation-fighting policy and stock-specific catalysts, hinting at continued volatility and selective accumulation. Viewers are left with a sense that positioning will hinge on macro moves and price reinforcements in the near term.
Dive Deeper:
Onto Innovation is characterized as a good company but deemed likely to go lower due to its high valuation in the current environment where the Fed is fighting inflation.
UiPath is described as a cheap stock but lacking catalysts, leading to a conclusion that it should be avoided or voted off the island in the near term.
Karman Holdings expresses strong conviction, signaling a belief that the stock is mispriced and worth backing despite broader market headwinds.
Affirm outlines a staged buy strategy, suggesting initial purchases at around $56, then incremental buys at $50 and $45, tied to confidence in CEO Max Levchin's numbers.
Nio is labeled a high-risk, low-price bet with the possibility of significant downside, with one panelist noting a zero-auspice scenario for $2 stocks.
Alnylam Pharmaceuticals is viewed as inexpensive, yet some participants favor Regeneron, Vertex, and Amgen as comparatively stronger choices.
The discussion blends price targets, risk tolerance, and macro considerations, signaling that stock picks will depend on price levels and evolving Fed policy.